Fintel reports that on January 22, 2025, RBC Capital downgraded their outlook for Intra-Cellular Therapies (NasdaqGS:ITCI) ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Regeneron (REGN – Research Report) on January 21 and set a price target of ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Incyte (INCY – Research Report) on January 21 and set a price target of $70.00.

Global stocks eased on Thursday, halting a rally sparked by U.S. President Donald Trump's mammoth spending plans for ...

Fintel reports that on January 21, 2025, RBC Capital downgraded their outlook for CF Industries Holdings (NYSE:CF) from ...

Each year, RBC supports thousands of students from different educational backgrounds in exploring various career paths within ...

CF Industries Holdings, Inc. (CF) stock saw a decline, ending the day at $93.66 which represents a decrease of $-3.35 or -3.45% from the prior close of $97.01. The stock opened at $95.5 and touched a ...

However, its 2025 costs and capital expenditure guidance exceeded analyst expectations as well as its own previous guidance. For full-year 2025, Hochschild expects capital expenditure between $197 ...

Financial writer discusses RBC Capital's bullish outlook on Carvana, citing upside potential in retail unit estimates and path to durable free cash flow.

For 2024, core inflation averaged 2.7%, pulling back sharply from the 4.2% rate seen in 2023. The headline measure came in at 2.4% versus 4.8% in 2023, suggesting that policymakers' efforts to tame ...

Investing.com -- RBC Capital Markets has downgraded both Anglo American (JO: AGLJ) plc and Antofagasta (LON: ANTO) plc to ...

US sanctions on Russian oil and tankers are causing Asian refiners to consider reducing operations due to high crude oil prices.